ClinicalTrials.gg
CompletedNCT05706506Updated Dec 13, 2024Results posted

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

A Phase 4 interventional study of Tirzepatide in Type 2 Diabetes and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
24th of 43
152 · median 160
Started
2023
with 5 others
Phase 4
10 of 43
4 open now
Registered
27th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 24th largest by enrollment, is one of 6 that started in 2023, is one of 10 in phase 4, and was the 27th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).

03

Conditions studied

  • Type 2 Diabetes
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 diabetes (T2D)
  • Have an c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)
  • Have a (BMI) ≥25 kilogram per square meter (kg/m²) at screening
  • Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months
  • No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D)
  • Have a clinical history of

    • proliferative diabetic retinopathy
    • diabetic maculopathy, or
    • non-proliferative diabetic retinopathy that requires acute treatment
  • Are at high risk for cardiovascular disease or have a history of

    • myocardial infarction
    • percutaneous coronary revascularization procedure
    • carotid stenting or surgical revascularization
    • nontraumatic amputation
    • peripheral vascular procedure
    • cerebrovascular accident
    • or hospitalization for congestive heart failure
  • Have (NYHA) Functional Classification Class IV congestive heart failure
  • Have a history of ketoacidosis or hyperosmolar state or coma
  • Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    5 milligrams (mg) Tirzepatide

    Participants received 5 mg tirzepatide subcutaneously administered once weekly for 12 weeks.

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))

    Change from Baseline in Percentage of Time per Day that CGM-derived Values were \>180 mg/dl (10 mmol/L) was assessed.

    Time frame: Baseline, Week 4

  2. Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)

    Change from Baseline in Percentage of Time per Day that CGM-derived Values were \>180 mg/dl (10 mmol/L) was assessed.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

    Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \>180 mg/dl (10 mmol/L) was assessed.

    Time frame: Baseline, Week 4

  4. Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

    Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \>180 mg/dl (10 mmol/L) was assessed.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Fasting Serum Glucose (FSG)

    Change from Baseline in FSG was assessed.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Weight

    Change from Baseline in Weight was assessed.

    Time frame: Baseline, Week 12

07

Results

Posted Dec 13, 2024

Participant flow

Participant flow — Overall Study
Milestone5 Milligrams (mg) Tirzepatide
Started152
Received at least 1 dose of study drug152
Completed131
Not completed21
Withdrew: Adverse event1
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up2
Withdrew: Inadvertent enrolment12
Withdrew: Early discontinuation due to hyperglycemia1
Withdrew: Participant moved out of state1

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1c5 mg Tirzepatide
Change From Baseline in Hemoglobin A1c (HbA1c)-0.43 ± 0.05
SecondaryChange From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))

Change from Baseline in Percentage of Time per Day that CGM-derived Values were \>180 mg/dl (10 mmol/L) was assessed.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Percentage of time per day
Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))
Percentage of time per day5 mg Tirzepatide
Change From Baseline in Percentage of Time Per Day That Continuous Glucose Monitoring (CGM)-Derived Values Were >180 Milligram/Deciliter (mg/dl) (10 Millimole/Liter (mmol/L))-6.52 ± 1.55
SecondaryChange From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)

Change from Baseline in Percentage of Time per Day that CGM-derived Values were \>180 mg/dl (10 mmol/L) was assessed.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percentage of time per day
Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)
Percentage of time per day5 mg Tirzepatide
Change From Baseline in Percentage of Time Per Day That CGM-derived Values Were >180 mg/dl (10 mmol/L)-7.37 ± 1.54
SecondaryChange From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \>180 mg/dl (10 mmol/L) was assessed.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Minutes per day
Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)
Minutes per day5 mg Tirzepatide
Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)-93.82 ± 22.30
SecondaryChange From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)

Change from Baseline in Duration of Time in Minutes per Day that CGM derived Values were \>180 mg/dl (10 mmol/L) was assessed.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Minutes per day
Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)
Minutes per day5 mg Tirzepatide
Change From Baseline in Duration of Time in Minutes Per Day That CGM Derived Values Were >180 mg/dl (10 mmol/L)-106.09 ± 22.21
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Change from Baseline in FSG was assessed.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligrams per deciliter (mg/dL)5 mg Tirzepatide
Change From Baseline in Fasting Serum Glucose (FSG)-7.83 ± 2.85
SecondaryChange From Baseline in Weight

Change from Baseline in Weight was assessed.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Weight
kilograms (kg)5 mg Tirzepatide
Change From Baseline in Weight-2.15 ± 0.28

Adverse events

Collected over Baseline Up To 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide0/152 (0%)1/152 (0.7%)0/152 (0%)
Most frequent serious events
Most frequent serious events
Event5 mg Tirzepatide
Coronary artery diseaseCardiac disorders1/152
Wound dehiscenceInjury, poisoning and procedural complications1/152

Baseline characteristics

All participants who received at least one dose of tirzepatide.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide
Mean58.1 ± 10.17
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide
Female84
Male68
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide
Hispanic or Latino32
Not Hispanic or Latino120
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide
American Indian or Alaska Native2
Asian9
Native Hawaiian or Other Pacific Islander0
Black or African American24
White117
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide
United States152
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)5 mg Tirzepatide
Mean7.40 ± 0.660
08

Study locations

32 sites
  • Fiel Family and Sports Medicine PC
    Tempe, Arizona 85283, United States
  • New Hope Research Development
    Corona, California 92882, United States
  • Velocity Clinical Research, Gardena
    Gardena, California 90247, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, Huntington Park
    Los Angeles, California 90057, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Dream Team Clinical Research
    Pomona, California 91767, United States
  • Scripps Whittier Diabetes Institute
    San Diego, California 92121-1520, United States
  • Metabolic Institute of America
    Tarzana, California 91356-3551, United States
  • CMR of Greater New Haven, LLC
    Waterbury, Connecticut 06708, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale Beach, Florida 33009, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32204, United States
  • Florida Institute For Clinical Research, LLC
    Orlando, Florida 32825, United States
  • New Tampa Health
    Tampa, Florida 33603-3402, United States
  • Georgia Clinical Research
    Lawrenceville, Georgia 30044-5896, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • Velocity Clinical Research, Valparaiso
    Valparaiso, Indiana 46383, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Versailles Family Medicine
    Versailles, Kentucky 40383-1947, United States
  • Endocrine and Metabolic Consultants
    Rockville, Maryland 20852, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Advanced Medical Research
    Maumee, Ohio 43537-9402, United States
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
  • Mountain View Clinical Research, Inc.
    Greenville, South Carolina 29607, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731-4309, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Memorial City Endocrine Consultants
    Houston, Texas 77043-2742, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • ClinPoint Trials
    Waxahachie, Texas 75165, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Oct 2023, 7 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 7 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Jan 31, 2023
StartActual
Mar 8, 2023
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Results first posted
Dec 13, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05706506
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Mar 8, 2023
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Results posted
Dec 13, 2024
Last update
Dec 13, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion